COVID-19

Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms

Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms

Shots: The P-II/III (SCORPIO-SR) trial evaluates Ensitrelvir (125/250mg) vs PBO in...

Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19

Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19

Shots: The 2nd P-III study evaluating safety & efficacy of VV116 (mindeudesivi...

Senhwa Bioscience’s Silmitasertib Received the US FDA IND Approval to treat patients with community-acquired pneumonia (CAP)

Senhwa Bioscience’s Silmitasertib Received the US FDA IND Approval to treat patients with community-acquired pneumonia (CAP)

Shots: The US FDA approved P-II IND evaluating silmitasertib (CX-4945) that aimed...

Moderna's Patent Revoked by the European Patent Office (EPO) due to BioNTech Vaccine Dispute

Moderna's Patent Revoked by the European Patent Office (EPO) due to BioNTech Vaccine Dispute

Shots: The European Patent Office declared that Moderna's mRNA patent was inva...

EpitoMAP, Animal Allergy Clinical Laboratories (AACL) & Kogyo Entered into a Collaboration and License Agreement to develop CRE-DR-B

EpitoMAP, Animal Allergy Clinical Laboratories (AACL) & Kogyo Entered into a Collaboration and License Agreement to develop CRE-DR...

Shots: As per the agreement, Kogyo has the right to conduct preclinical & clin...

Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19

Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19

Shots:   Fresenius Kabi has launched Tyenne, first tocilizumab biosimila...

Image